Fig. 6: Acquired resistance mechanism to dual EGFR blockade. | Nature Communications

Fig. 6: Acquired resistance mechanism to dual EGFR blockade.

From: Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer

Fig. 6

a Distribution of established resistance mechanism in patients providing serial blood samples for genomic profiling (n = 38). *Potential resistance mediators were defined as mutations that were newly detected or increased in VAF by 1.5 times at progression and defined as pathogenic mutations by OncoKB53 and COSMIC database;54 b Potential mediators of resistance were subjected to KEGG pathway analysis56. Altered pathways in patients with downstream signaling activation (n = 6), cell cycle dysregulation (n = 8) and DNA repair defects (n = 1) are detected. Source data are provided as a source data file.

Back to article page